MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-24
DOI
10.1007/s00432-023-04714-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Clinical significance of MYD88 non‐L265P mutations in diffuse large B‐cell lymphoma
- (2022) Jialing Xie et al. HEMATOLOGICAL ONCOLOGY
- Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
- (2020) Stuart E. Lacy et al. BLOOD
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
- (2020) George W. Wright et al. CANCER CELL
- Molecular profiling of Chinese R‐CHOP treated DLBCL patients: identifying a high‐risk subgroup
- (2020) Shiyu Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib
- (2020) Shiyu Jiang et al. Targeted Oncology
- Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
- (2019) YunXiang Zhang et al. Frontiers in Pharmacology
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
- (2016) Sydney Dubois et al. CLINICAL CANCER RESEARCH
- MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
- (2016) J. Rovira et al. CLINICAL CANCER RESEARCH
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma
- (2010) C. R. Flowers et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Regulation of Adaptive Immunity by the Innate Immune System
- (2010) A. Iwasaki et al. SCIENCE
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started